Modafinil/armodafinil in the treatment of narcolepsy

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Modafinil has been available in the USA since 1998 and is now regarded as the first-line therapy for the treatment of excessive sleepiness associated with narcolepsy. Modafinil does not help cataplexy or other ancillary features of narcolepsy, such as hypnagogic hallucinations or sleep paralysis. In 2004, the indication for modafinil was expanded to include the treatment of excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSAHS) and shift-work sleep disorder (SWSD). Since that time modafinil has become the most widely prescribed agent in the U.S. for excessive sleepiness of all types. In 2007, armodafinil, the r-enantiomer of modafinil (racemic), was approved for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome (OSAHS) and shift-work sleep disorder (SWSD). However, armodafinil is not yet available in pharmacies for use.

Original languageEnglish (US)
Title of host publicationNarcolepsy
Subtitle of host publicationA Clinical Guide
PublisherSpringer New York
Pages287-294
Number of pages8
ISBN (Print)9781441908537
DOIs
StatePublished - Dec 1 2010

    Fingerprint

Keywords

  • Armodafinil
  • Modafinil
  • Narcolepsy
  • Sleepiness

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Thorpy, M. (2010). Modafinil/armodafinil in the treatment of narcolepsy. In Narcolepsy: A Clinical Guide (pp. 287-294). Springer New York. https://doi.org/10.1007/978-1-4419-0854-4_25